Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 3
2019 1
2020 2
2021 3
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, Klaase L, de Bruijn M, van Nimwegen M, van Tienhoven T, van Ijcken W, Boon L, van der Schoot J, Verdoes M, Scheeren F, van der Burg SH, Lambrecht BN, Stadhouders R, Dammeijer F, Aerts J, van Hall T. van Gulijk M, et al. Among authors: dammeijer f. Sci Immunol. 2023 May 19;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173. Epub 2023 May 19. Sci Immunol. 2023. PMID: 37205768
Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma.
van Krimpen A, Gerretsen VIV, Mulder EEAP, van Gulijk M, van den Bosch TPP, von der Thüsen J, Grünhagen DJ, Verhoef C, Mustafa D, Aerts JG, Stadhouders R, Dammeijer F. van Krimpen A, et al. Among authors: dammeijer f. Cancer Cell. 2022 Aug 8;40(8):798-799. doi: 10.1016/j.ccell.2022.06.009. Epub 2022 Jul 14. Cancer Cell. 2022. PMID: 35839777 Free article. No abstract available.
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
Cantini L, Pecci F, Dammeijer F, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: dammeijer f. Eur J Cancer. 2021 Aug;153:267-269. doi: 10.1016/j.ejca.2021.05.016. Epub 2021 Jun 18. Eur J Cancer. 2021. PMID: 34154882 No abstract available.
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, Aerts JG. Dammeijer F, et al. EBioMedicine. 2021 Feb;64:103160. doi: 10.1016/j.ebiom.2020.103160. Epub 2021 Jan 27. EBioMedicine. 2021. PMID: 33516644 Free PMC article.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA; NVALT19 study group. de Gooijer CJ, et al. Among authors: dammeijer f. Lancet Respir Med. 2021 Jun;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515500 Clinical Trial.
20 results